IMNN Imunon Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMNN

Price (delayed)

$1.33

Market cap

$12.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.16

Enterprise value

$8.29M

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of ...

Highlights
IMNN's debt has plunged by 74% YoY and by 6% from the previous quarter
The company's EPS has surged by 57% YoY and by 34% QoQ
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
Imunon's revenue has plunged by 100% from the previous quarter and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.celsion.com
Peers: OPK

Key stats

What are the main financial stats of IMNN
Market
Shares outstanding
9.4M
Market cap
$12.5M
Enterprise value
$8.29M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$20.6M
EBITDA
-$19.88M
Free cash flow
-$19.47M
Per share
EPS
-$2.16
Free cash flow per share
-$2.15
Book value per share
$1.42
Revenue per share
$0
TBVPS
$2.42
Balance sheet
Total assets
$21.92M
Total liabilities
$8.53M
Debt
$1.62M
Equity
$13.39M
Working capital
$10.85M
Liquidity
Debt to equity
0.12
Current ratio
2.47
Quick ratio
2.12
Net debt/EBITDA
0.21
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-66.5%
Return on equity
-98%
Return on invested capital
-127.3%
Return on capital employed
-141.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMNN stock price

How has the Imunon stock price performed over time
Intraday
1.53%
1 week
-7.64%
1 month
-4.32%
1 year
5.56%
YTD
95.59%
QTD
-18.9%

Financial performance

How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.03M
Net income
-$19.51M
Gross margin
N/A
Net margin
N/A
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
Imunon's revenue has plunged by 100% from the previous quarter and by 100% YoY
The net income has grown by 46% YoY and by 30% from the previous quarter
IMNN's operating income is up by 16% YoY and by 4.4% QoQ

Growth

What is Imunon's growth rate over time

Valuation

What is Imunon stock price valuation
P/E
N/A
P/B
0.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 57% YoY and by 34% QoQ
IMNN's price to book (P/B) is 86% higher than its last 4 quarters average of 0.5 but 28% lower than its 5-year quarterly average of 1.3
The equity has dropped by 54% year-on-year and by 26% since the previous quarter
Imunon's revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Imunon business performance
IMNN's ROIC is down by 32% YoY but it is up by 9% QoQ
Imunon's return on assets has increased by 17% QoQ but it has decreased by 8% YoY
The ROE has grown by 16% from the previous quarter but it has contracted by 12% YoY

Dividends

What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNN.

Financial health

How did Imunon financials performed over time
The total assets is 157% more than the total liabilities
The total assets has plunged by 50% YoY and by 11% from the previous quarter
The company's total liabilities fell by 42% YoY but it rose by 30% QoQ
IMNN's debt is 88% less than its equity
IMNN's debt has plunged by 74% YoY and by 6% from the previous quarter
The equity has dropped by 54% year-on-year and by 26% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.